Update on Resistance among Nosocomial Gram-Negative Pathogens to Extended-Spectrum Cephalosporins and Fluoroquinolones: Results of the Antimicrobial Resistance Management (ARM) Program

Abstract

Objective

To evaluate trends in antibiotic resistance among Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Pseudomonas aeruginosa isolates submitted to the Antimicrobial Resistance Management (ARM) program between 1990 and 2002.

Design

The ongoing Antimicrobial Resistance Management (ARM) program is a queriable Web-based surveillance system that tracks resistance patterns among U.S. inpatient and outpatient isolates. This report represents data from 285 institutions and over 17 million isolates. Using a Web-based analysis tool, antibiogram and sensitivity reports of E. coli, K. pneumoniae, P. mirabilis, and P. aeruginosa isolates were reviewed for resistance to extended-spectrum cephalosporins and fluoroquinolones.

Setting

285 teaching and non-teaching U.S Hospitals nationwide.

Results

For E. coli, resistance was 3.2% to ciprofloxacin (n = 444,947), 5.4% to levofloxacin (n = 201,532), and 0.8% to cefotaxime (n = 107,394), ceftriaxone (n = 464,931), and cefepime (n = 81,980), respectively. K. pneumoniae isolate resistance was 4.6% to ciprofloxacin (n = 144,698), 4.5% to levofloxacin (n = 57,462), 1.9% to cefotaxime (n = 33,189), 2.0% to ceftriaxone (n = 145,328) and 1.9% to cefepime (n = 25,503). For P. mirabilis, resistance was 12.5% to ciprofloxacin (n = 83,186), 12.2% to levofloxacin (n = 35,277), 1.0% to cefotaxime (n = 18,802), 0.7% to ceftriaxone (83,652), and 2.3% to cefepime (n = 13,968). P. aeruginosa resistance was also higher for fluoroquinolones (only 65.2% of isolates were susceptible to ciprofloxacin) compared to extended-spectrum cephalosporins, with ceftazidime exhibiting the greatest antipseudomonal activity. Clinically significant regional variations in the activity of fluoroquinolones and cephalosporins were apparent.

Conclusion

Resistance to the fluoroquinolones is increasing dramatically, whereas the third generation cephalosporins remain inherently more active. P. aeruginosa exhibits the most formidable resistance pattern with neither the antipseudomonal cephalosporins nor fluoroquinolones representing acceptable monotherapy options. Given the association between fluoroquinolone resistance and extended-spectrum β-lactamase production, continued surveillance is vital to preserve the activity of existing therapies.

Keywords

resistance fluoroquinolones cephalosporins nosocomial Gram-negative

Get full access to this article

View all access options for this article.

References

Pinner

R.W.

, Teutsch

S.M.

, Simonsen

Trends in infectious diseases mortality in the United States. JAMA. 1996; 275: 189–193.

Simonsen

, Conn

L.A.

, Pinner

R.W.

, Teutsch

Trends in infectious disease hospitalizations in the United States, 1980-1994. Arch Intern Med. 1998; 28;158: 1923–1928.

Engemann

J.J.

, Carmeli

, Cosgrove

S.E.

Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus site infection. Clin Infect Dis. 2003; 36: 592–598.

Niederman

M.S.

Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit Care Med. 2001; 29 Suppl 4: N114–N120.

Donskey

C.J.

, Chowdhry

T.K.

, Hecker

M.T.

Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med. 2000; 343: 1925–1932.

Bhalla

, Pultz

N.J.

, Ray

A.J.

, Hoyen

C.K.

, Eckstein

C.K.

, Donskey

C.J.

Antianaerobic antibiotic therapy promotes overgrowth of antibiotic-resistant, Gram-negative bacilli and vancomycin-resistant enterococci in the stool of colonized patients. Infect Control Hosp Epidemiol. 2003; 24: 644–649.

Rahal

J.J.

, Urban

, Horn

Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA. 1998; 280: 1233–1237.

Knothe

, Shah

, Krcmery

, Antal

, Mitsuhashi

Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection. 1983; 11: 315–317.

Philippon

, Labia

, Jacoby

Extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1989; 33: 1131–1136.

10.

Rupp

M.E.

, Fey

P.D.

Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs. 2003; 63: 353–365.

11.

Paterson

D.L.

, Mulazimoglu

, Casellas

J.M.

Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis. 2000; 30: 473–478.

12.

Jones

R.N.

, Varnam

D.J.

Antimicrobial activity of broad-spectrum agents tested against Gram-negative bacilli resistant to ceftazidime: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Diagn Microbiol Infect Dis. 2002; 44: 379–382.

13.

Winokur

P.L.

, Canton

, Casellas

J.M.

, Legakis

Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis. 2001; 32 Suppl 2: S94–S103.

14.

Centers for Disease Control and Prevention. Antimicrobial resistance interagency task force 2002 Annual report on a public health action plan to combat antimicrobial resistance. Available at: www.cdc.gov/drugresistance/action-plan/2002report/index.htm. Accessed on March 20, 2004.

15.

National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, PA.

16.

National Committee for Clinical Laboratory Standards. 2000. Performance standards for antimicrobial disk susceptibility tests, 7th ed. Approved standard M2-A7. National Committee for Clinical Laboratory Standards, Wayne, PA.

17.

National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing. Twelfth informational supplement M100-S12. National Committee for Clinical Laboratory Standards, Wayne, PA.

18.

National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. NCCLS, Wayne, PA. Ninth informational supplement 1999; MS100.

19.

Sader

H.S.

, Biedenbach

D.J.

, Jones

R.N.

Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001). Diagn Microbiol Infect Dis. 2003; 47: 361–364.

20.

Mathai

, Jones

R.N.

, Pfaller

; SENTRY Participant Group North America. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America). Diagn Microbiol Infect Dis. 2001; 40: 129–136.

21.

Wisplinghoff

, Edmond

M.B.

, Pfaller

M.A.

, Jones

R.N.

, Wenzel

R.P.

, Seifert

Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis. 2000; 31: 690–697.

22.

Sader

H.S.

, Pfaller

M.A.

, Jones

R.N.

Bacterial Pathogens Isolated from Patients with Bloodstream Infections in Latin America, 1997: Frequency of Occurrence and Antimicrobial Susceptibility Patterns from the SENTRY Antimicrobial Surveillance Program. Braz J Infect Dis. 1999; 3: 97–110.

23.

Mathai D, Lewis MT, Kugler KC, Pfaller MA, Jones RN; SENTRY Participants Group (North America). Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I–results from the SENTRY Antimicrobial Surveillance Program (North America, 1998). Diagn Microbiol Infect Dis. 2001; 39: 105–116.

24.

Chen

D.K.

, McGeer

, de Azavedo

J.C.

, Low

D.E.

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med. 1999; 341: 233–239.

25.

Davidson

, Cavalcanti

, Brunton

J.L.

Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med. 2002; 346: 747–750.

26.

Zhanel

G.G.

, Palatnick

, Nichol

K.A.

, Bellyou

, Low

D.E.

, Hoban

D.J.

Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother. 2003; 47: 1867–1874.

27.

Weiss

, Restieri

, Gauthier

A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clin Infect Dis. 2001; 33: 517–522.

28.

Steinman

M.A.

, Gonzales

, Linder

J.A.

, Landefeld

C.S.

Changing use of antibiotics in community-based outpatient practice, 1991–1999. Ann Intern Med. 2003; 138: 525–533.

29.

Steinman

M.A.

, Landefeld

C.S.

, Gonzales

Predictors of broad-spectrum antibiotic prescribing for acute respiratory tract infections in adult primary care. JAMA. 2003; 289: 719–725.

30.

Hooper

D.C.

Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis. 2002; 2: 530–538.

31.

Steward

C.D.

, Wallace

, Hubert

S.K.

Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of project ICARE laboratories. Diagn Microbiol Infect Dis. 2000; 38: 59–67.

32.

Tenover

F.C.

, Mohammed

M.J.

, Gorton

T.S.

, Dembek

Z.F.

Detection and reporting of organisms producing extended-spectrum beta-lactamases: survey of laboratories in Connecticut. J Clin Microbiol. 1999; 37: 4065–4070.

33.

Steward

C.D.

, Rasheed

J.K.

, Hubert

S.K.

Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum beta-lactamase detection methods. J Clin Microbiol. 2001; 39: 2864–2872.

34.

Paterson

D.L.

, Ko

W.C.

, Von Gottberg

Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol. 2001; 39: 2206–2212.

35.

Einhorn

A.E.

, Neuhauser

M.M.

, Bearden

D.T.

, Quinn

J.P.

, Pendland

S.L.

Extended-spectrum beta-lactamases: frequency, risk factors, and outcomes. Pharmacotherapy. 2002; 22: 14–20.

36.

Paterson

D.L.

, Ko

W.C.

, Von Gottberg

International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med. 2004; 140: 26–32.

37.

Wang

, Sahm

D.F.

, Jacoby

G.A.

, Hooper

D.C.

Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob Agents Chemother. 2004; 48: 1295–1299.

38.

Martinez-Martinez

, Pascual

, Jacoby

G.A.

Quinolone resistance from a transferable plasmid. Lancet. 1998; 351: 1797–1799.

39.

Firsov

A.A.

, Vostrov

S.N.

, Lubenko

I.Y.

, Drlica

, Portnoy

Y.A.

, Zinner

S.H.

In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother. 2003; 47: 1604–1613.

40.

Drlica

The mutant selection window and antimicrobial resistance. J Antimicrob Chemother. 2003; 52: 11–17.

41.

Epstein

B.J.

, Gums

J.G.

, Drlica

The changing face of antiobiotic prescribing: the mutant selection window. Ann Pharmacother. 2004; 38: 1675–1682.